# Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients

> **NCT02413645** · PHASE1 · COMPLETED · sponsor: **Judit Pich Martínez** · enrollment: 21 (actual)

## Conditions studied

- HIV-infection

## Interventions

- **BIOLOGICAL:** TriMix_100
- **BIOLOGICAL:** TriMix_300
- **BIOLOGICAL:** 600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)
- **BIOLOGICAL:** 900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)
- **BIOLOGICAL:** 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA)

## Key facts

- **NCT ID:** NCT02413645
- **Lead sponsor:** Judit Pich Martínez
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2016-06
- **Final completion:** 2016-10
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02413645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02413645, "Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02413645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*